Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine in metastatic HER2-positive breast cancer patients.

Trial Profile

Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine in metastatic HER2-positive breast cancer patients.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2015 New trial record
    • 03 Jun 2014 Results in 5 patients presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top